BRCA1 and breast carcinoma: By contrast, in a transgenic murine breast cancer model, nonsynonymous missense mutation in the Brca1 RING domain (C61G) was associated with poorer response to cisplatin and PARP inhibitor therapy than a complete Brca1 knockout, despite similar tumour morphology and copy number alterations20.